Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TriSalus Life Sciences (TLSI) Invested Capital (2021 - 2026)

TriSalus Life Sciences has reported Invested Capital over the past 6 years, most recently at $45.9 million for Q1 2026.

  • For Q1 2026, Invested Capital rose 1817.93% year-over-year to $45.9 million; the TTM value through Mar 2026 reached $45.9 million, up 1817.93%, while the annual FY2025 figure was -$815000.0, 78.61% up from the prior year.
  • Invested Capital for Q1 2026 was $45.9 million at TriSalus Life Sciences, up from -$815000.0 in the prior quarter.
  • Over five years, Invested Capital peaked at $45.9 million in Q1 2026 and troughed at -$188.4 million in Q2 2023.
  • A 5-year average of -$57.7 million and a median of -$4.0 million in 2024 define the central range for Invested Capital.
  • Biggest five-year swings in Invested Capital: crashed 85.0% in 2024 and later skyrocketed 1817.93% in 2026.
  • Year by year, Invested Capital stood at -$174.7 million in 2022, then surged by 84.51% to -$27.1 million in 2023, then surged by 85.92% to -$3.8 million in 2024, then soared by 78.61% to -$815000.0 in 2025, then surged by 5730.18% to $45.9 million in 2026.
  • Business Quant data shows Invested Capital for TLSI at $45.9 million in Q1 2026, -$815000.0 in Q4 2025, and $6.0 million in Q3 2025.